Korglutide is an innovative oral dual agonist peptide that acts simultaneously on GLP-1 and IGF-1 receptors, providing a synergistic mechanism for safe and effective weight loss without muscle loss. Through GLP-1 receptor activation, Korglutide suppresses appetite, delays gastric emptying, enhances satiety, and stimulates insulin secretion, leading to improved glycemic control and reduced caloric intake. It also promotes lipolysis and inhibits lipogenesis, effectively breaking down fat and preventing new fat accumulation. At the same time, IGF-1 receptor activation triggers anabolic signaling through the mTOR and ERK pathways, promoting muscle protein synthesis and upregulating key myogenic regulators such as MyoD, MyoG, SIRT1, and MyHC, which maintain muscle mass. Clinically, this dual-receptor activity results in significant fat mass reduction (−6.65 kg) with minimal muscle loss (−0.27 kg), achieving an average −10.75% body weight decrease and −0.9% HbA1c reduction in 12 weeks. Moreover, Korglutide improves lipid metabolism, reduces visceral fat and waist-to-hip ratio, and causes far fewer gastrointestinal side effects compared to injectable GLP-1 analogs like semaglutide or liraglutide. Its oral, peptide-based formulation offers a convenient, injection-free alternative that combines metabolic regulation, fat targeting, and muscle preservation for comprehensive weight management.